Video content material above is prompted by the next questions:
- How would you describe your present medical method for high-risk sufferers with CLL/SLL, together with these with or with out del(17p) and/or TP53 mutations?
- What are the targets of remedy for sufferers on this setting?
- What are some challenges and unmet wants for sufferers with CLL/SLL?
